Zentalis Pharmaceuticals Inc

Ouvert

4.39 -12.02

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.35

Max

5.1

Chiffres clés

By Trading Economics

Revenu

-136K

-35M

BPA

-0.503

Employés

106

EBITDA

2.2M

-35M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+44.33% upside

Dividendes

By Acuity

Prochains Résultats

4 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

33M

328M

Ouverture précédente

16.41

Clôture précédente

4.39

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 juin 2026, 23:56 UTC

Ulta Beauty shares rose in after-market trading, though they remain below the 20-day moving average and near the lower end of their one-month range.

30 juin 2026, 23:56 UTC

Correlated Moves

After-market trading for the iShares Core U.S. Aggregate Bond ETF is roughly flat, reflecting routine performance amid slight gains in the US 2Y Treasury Bond.

30 juin 2026, 23:52 UTC

European equity indices rise as Germany's inflation falls below expectations, easing ECB tightening concerns, while Bitcoin declines amid market volatility.

30 juin 2026, 23:52 UTC

Global markets show mixed performance as European indices rise on tech optimism while U.S. stocks decline amid volatility, with the dollar strengthening against the yen and Bitcoin falling due to regulatory concerns.

30 juin 2026, 23:52 UTC

U.S. equity indices decline as tech stocks sell off, while European markets rise on positive economic data; dollar strengthens amid Fed rate hike expectations and Bitcoin drops 2.8%.

30 juin 2026, 23:52 UTC

Mixed Asia equity markets as Japan's optimism contrasts with U.S. profit-taking; Bitcoin declines amid shifting investor focus ahead of key U.S. employment data.

30 juin 2026, 23:52 UTC

Bank of Japan to release Q2 Tankan Index on June 30, with market expectations set at a stable 16.0 amid ongoing optimism in manufacturing sector.

30 juin 2026, 23:52 UTC

South Korea's Exports Expected to Surge Again Ahead of July 1 Release Amid Strong Semiconductor Demand and Positive Market Sentiment.

30 juin 2026, 23:52 UTC

South Korea's S&P Global Manufacturing PMI set for July 1, with positive trends expected amid regional growth signals and inflation concerns.

30 juin 2026, 23:52 UTC

ISM Manufacturing Employment Report Set for July 1: Market Eyes Mixed Economic Signals and Job Growth Ahead of Potential Fed Rate Hikes.

30 juin 2026, 23:52 UTC

Australia's Balance of Trade data set for July 2, 2026, anticipates a AUD 2.3 billion surplus amid mixed stock market sentiment and geopolitical concerns.

30 juin 2026, 23:52 UTC

ISM Manufacturing PMI for June 2026 set to release on July 1, forecasted at 54.0 amid cautious optimism and geopolitical tensions impacting market stability.

30 juin 2026, 23:52 UTC

Brazil's BCB Focus Market Readout on July 6, 2026, may signal interest rate adjustments amid mixed investor sentiment influenced by inflation and global market pressures.

30 juin 2026, 23:52 UTC

Brazil's Industrial Production Expected to Continue Growth Trend Ahead of July 2 Release Amid Record Oil Output from Petrobras

30 juin 2026, 23:52 UTC

Canada's Manufacturing PMI Release on July 2 Expected to Reflect Economic Resilience Amid Mixed Global Signals and Geopolitical Pressures.

30 juin 2026, 23:52 UTC

ECB Forum on Central Banking Set for July 2026 Amid Cautious Market Sentiment and Potential Changes to Interest Rates.

30 juin 2026, 23:52 UTC

Japan's Current Account Data Release on July 7, 2026, Expected to Reflect Economic Trends Amidst Cautious Investor Optimism.

30 juin 2026, 23:51 UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Europe ETF is lower in after-market hours, influenced by mixed returns from holdings like BCS and NOK, as well as broader market sentiment.

30 juin 2026, 23:51 UTC

ETF Constituents

Vanguard Small-Cap ETF declines after hours, impacted by significant losses in holdings like SSTK, BLDR, and TOL. Trading activity remains weak.

30 juin 2026, 23:51 UTC

ETF Constituents

VanEck Gold Miners ETF declines in after-market trading, following three consecutive lower daily closes. KGC, AEM, and NEM all recorded negative returns.

30 juin 2026, 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

30 juin 2026, 23:51 UTC

Texas Instruments Inc. shares are trading higher in after-market hours, reflecting broader positive momentum in equity indices amid optimism around economic data and AI investments.

30 juin 2026, 23:46 UTC

NetEase Inc. shares are higher in after-market trading, reflecting unusual strength following three consecutive sessions of gains amid a positive trend in European equities.

30 juin 2026, 23:46 UTC

Lululemon Athletica Inc shares are lower in after-market hours, remaining near the lower end of their one-month range and below the 20-day moving average.

30 juin 2026, 23:46 UTC

ETF Constituents

iShares MSCI South Korea ETF declines after market close, influenced by mixed global equity performance. LG Display saw a positive return, while SK Telecom had minimal impact.

30 juin 2026, 23:46 UTC

ETF Constituents

iShares China Large-Cap ETF advances in after-market trading, influenced by JD's negative contribution. FXI remains near the lower end of its one-month range.

30 juin 2026, 23:42 UTC

Australia's Ai Group Industry Index plunges to -30.0, signaling severe industrial contraction amid mixed economic signals and persistent challenges.

30 juin 2026, 23:42 UTC

MBA 30-Year Mortgage Rate Release on July 1 Expected to Show Stability Amid High Borrowing Costs and Mixed Consumer Confidence in Housing Market

30 juin 2026, 23:42 UTC

Mexican Business Confidence Remains Low at 47.5 Points Ahead of Key EMOE Report Amid Regulatory Changes and Economic Uncertainties

30 juin 2026, 23:42 UTC

Australia's Building Permits Expected to Rise 0.01% Amid Cautious Economic Sentiment and Mixed Market Indicators

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

44.33% hausse

Prévisions sur 12 Mois

Moyen 7 USD  44.33%

Haut 10 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

4

Achat

3

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat